Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6189968 | Bulletin du Cancer | 2016 | 11 Pages |
Abstract
Ibrutinib is a new-targeted therapy that irreversibly and specifically inhibits the Bruton's Tyrosine Kinase (BTK), a key component of the signaling pathways of B cells. The results are very encouraging as monotherapy in the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström's macroglobulinemia. Following the results of recent studies, ibrutinib is now available in France for these three diseases.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Aurore Dougé, Aurélie Ravinet, Jacques-Olivier Bay, Olivier Tournilhac, Romain Guièze, Richard Lemal,